Choosing the right drug to fit the patient when selecting oral anticoagulation for stroke prevention in atrial fibrillation.
about
Edoxaban in venous thromboembolism and stroke prevention: an appraisalEmerging Tools for Stroke Prevention in Atrial FibrillationRisk-Benefit Profile of Direct-Acting Oral Anticoagulants in Established Therapeutic Indications: An Overview of Systematic Reviews and Observational StudiesStroke Prevention in Atrial Fibrillation: Focus on Latin AmericaEffect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial FibrillationComparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort studyChronic Kidney Disease, Time in Therapeutic Range and Adverse Clinical Outcomes in Anticoagulated Patients with Non-valvular Atrial Fibrillation: Observations from the SPORTIF TrialsIndividualising Anticoagulant Therapy in Atrial Fibrillation PatientsApixaban versus edoxaban for stroke prevention in nonvalvular atrial fibrillation.The Patterns of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) Use in Patients with Atrial Fibrillation in Seven Balkan Countries: a Report from the BALKAN-AF SurveyEffectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study.A tailored treatment strategy: a modern approach for stroke prevention in patients with atrial fibrillation.Betrixaban - the next direct factor Xa inhibitor?Overcoming global challenges in stroke prophylaxis in atrial fibrillation: The role of non-vitamin K antagonist oral anticoagulants.Switching, Adverse Effects and Use of Over-the-Counter Analgesics among Users of Oral Anticoagulants: A Pharmacy-based Survey.The factor xa inhibitor edoxaban for the prevention of stroke and systemic embolism in patients with atrial fibrillation.Safety profile of the direct oral anticoagulants: an analysis of the WHO database of adverse drug reactions.Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.Use of direct oral anticoagulants in the first year after market entry of edoxaban: A Danish nationwide drug utilization study.The CHA₂DS₂-VASc score for stroke risk stratification in patients with atrial fibrillation: a brief history.Trends in initiation of direct oral anticoagulant therapies for atrial fibrillation in a national population-based cross-sectional study in the French health insurance databases.[Consensus statement: Management of oral anticoagulation for stroke prevention in patients with nonvalvular atrial fibrillation].Once- versus twice-daily direct oral anticoagulants in non-valvular atrial fibrillation.Direct oral anticoagulants (DOACs).Atrial fibrillation
P2860
Q26751263-FD1A2E79-B9D7-4978-A83D-D717A0793929Q26765023-547E7BAB-F77E-4EBC-B571-52E7FE36EA5EQ28078747-0296DE19-2F5A-48CB-AA8B-A37CD29DB2FCQ28359631-FA8233FE-237A-417C-8664-5BD3B015534AQ36714127-72951D16-402D-4C16-98C5-0C3D4FB65F37Q37012525-B4B056A5-EBCE-4CD3-AC88-4293DB23B706Q37035168-57E59FD8-4D53-4468-86F5-98DC16EE5368Q37235927-69D814D9-7B17-460E-9D3A-D46FD1204443Q38566808-89C6A7F2-1039-496B-BD56-FCFACA1C43DFQ38631121-8CEC2A2E-D4C9-4B92-BB52-0E439F03446EQ38725712-285C78C5-B0D6-40A2-8A8D-51D964086367Q38784172-F760CD55-ED8C-43BD-8415-65D221AE6E32Q38799138-4253BECF-42FE-4800-8886-AA324D68BC4EQ38972270-79843A92-6192-44F5-838A-E1F072864A89Q38993349-65D64ECD-67DE-4912-8E34-914747953005Q39000179-37065EFD-642F-4ADB-83A1-8ED4605EB759Q39029615-26F108DB-0FAE-487F-9A31-8F5B997BF22DQ40668973-B067072E-D01B-4DB3-A356-20E1E59033A6Q48298756-81D5B110-F848-40B6-9ADD-B5C5E64F7C8EQ50856123-42D060FB-FCEA-488B-94E4-C79D17F6A713Q52618065-7ED5D3D0-3434-4897-88F5-0769D9E7B59AQ52848195-F1C13AE6-D9F1-4127-A0EC-991D2A57EF25Q53559263-729A4579-DE78-422B-B41C-11913F60A2D8Q54059118-491FDE30-8FEA-4226-876C-868A9FF9CC89Q58645594-7E0B1221-070A-4F67-9790-7BD8D464B41E
P2860
Choosing the right drug to fit the patient when selecting oral anticoagulation for stroke prevention in atrial fibrillation.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Choosing the right drug to fit ...... ention in atrial fibrillation.
@en
type
label
Choosing the right drug to fit ...... ention in atrial fibrillation.
@en
prefLabel
Choosing the right drug to fit ...... ention in atrial fibrillation.
@en
P2860
P921
P356
P1476
Choosing the right drug to fit ...... ention in atrial fibrillation.
@en
P2093
A M Shields
P2860
P356
10.1111/JOIM.12360
P407
P577
2015-04-15T00:00:00Z